# A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC)

> **NCT06472076** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **GlaxoSmithKline** · enrollment: 88 (actual)

## Conditions studied

- Lung Cancer, Non-Small Cell

## Interventions

- **BIOLOGICAL:** Dostarlimab
- **BIOLOGICAL:** Belrestotug
- **BIOLOGICAL:** Pembrolizumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06472076
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-06-10
- **Primary completion:** 2027-02-02
- **Final completion:** 2027-02-02
- **Target enrollment:** 88 (ACTUAL)
- **Last updated:** 2025-09-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06472076

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06472076, "A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06472076. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*